Loading...

CRBP CORBUS PHARMACEUTICALS HOLDINGS INC Investments/Divestments 8-K Filing

CRBS

CRBP

CORBUS PHARMACEUTICALS HOLDINGS INC

(CRBP)

2023 8-K

Show Summary

Summary

Financial Statements

Management Change

Financial Results

Clinical Trial Update

Share Sale Plan

Financial Results

Stock Sale Plan

Presentation Update

Financial Results

Rule 10b5-1 Plan

Phase 1 Clinical Trial Data...

Equity Compensation Plan Ap...

Risk Factors Update

Financial Results

Amended Employment Agreements

Rule 10b5-1 Plans Adopted

Financial Results

Update on Investor Presenta...

Amendment Filing

Underwriting Agreement

Termination of Prospectus S...

Financial Update

Clinical Trial Data Announc...

Delisting Notice

Update of Presentation

Delisting Notice

Financial Results

Financial Results

Financial Results

Financial Results and Manag...

Appointment of Director

Exclusive License Agreement...

Delisting Notice

External Links:

Corbus Pharmaceuticals entered into an Exclusive License Agreement with CSPC Megalith Biopharmaceutical to develop and commercialize CRB-701, paying an upfront fee of $7.5 million and potential milestone payments of up to $685 million.

AI Assistant

CORBUS PHARMACEUTICALS HOLDINGS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.